Quadrant Biosciences Inc., of Syracuse, N.Y., is collaborating with the Autism Speaks Autism Treatment Network. Quadrant will provide financial support for the Signature Study, testing the antibiotic minocycline on patients with autism spectrum disorder, and will collect salivary RNA data to further elucidate epigenetic factors associated with the disease.